US Patent

US8983594 — Electronic control of drug delivery system

Method of Use · Assigned to NuPathe Inc · Expires 2030-11-19 · 5y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a drug delivery device that uses electrotransport to release a therapeutic agent, such as sumatriptan succinate, through a user's body surface.

USPTO Abstract

In an exemplary embodiment, a drug delivery device for driving an electrotransport current through a body surface of a user is provided. The device includes a patch with two electrodes and one or more reservoirs storing a therapeutic agent. The one or more reservoirs release the therapeutic agent into the body surface of the user when the reservoirs are positioned over the electrodes to form an electrical path for the electrotransport current. The device includes a controller which controls a controllable power supply to drive the electrotransport current through the body surface of the user in a predetermined profile.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1328 sumatriptan-succinate

Patent Metadata

Patent number
US8983594
Jurisdiction
US
Classification
Method of Use
Expires
2030-11-19
Drug substance claim
No
Drug product claim
Yes
Assignee
NuPathe Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.